Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic

被引:44
作者
Rodriguez, M. [1 ]
Monedero, I. [2 ,3 ]
Caminero, J. A. [2 ,4 ]
Encarnacion, M. [1 ]
Dominguez, Y. [1 ]
Acosta, I. [5 ]
Munoz, E. [1 ]
Camilo, E. [1 ]
Martinez-Selmo, S. [1 ]
de los Santos, S. [1 ]
del Granado, M. [6 ]
Casals, M. [7 ,8 ]
Cayla, J. [7 ]
Marcelino, B. [1 ]
机构
[1] Dominican Republ Natl TB Programme, Santo Domingo, Dominican Rep
[2] Int Union TB & Lung Dis, Dept TB & HIV, MDR TB Unit, F-75006 Paris, France
[3] Univ Autonoma Barcelona, Dept Pediat Ginecol & Med Prevent, E-08193 Barcelona, Spain
[4] Hosp Gen Gran Canaria Dr Negrin, Serv Neumol, Las Palmas Gran Canaria, Spain
[5] Com Nacl Evaluac TB MDR, Santo Domingo, Dominican Rep
[6] Panamer Hlth Org, Washington, DC USA
[7] Ctr Invest Biomed Red Epidemiol & Salud Publ, Barcelona, Spain
[8] Univ Barcelona, Dept Salut Publ, Barcelona, Spain
关键词
Dominican Republic; multidrug-resistant tuberculosis; MDR-TB; standardised treatment; tuberculosis; TB; RETROSPECTIVE COHORT; TREATMENT OUTCOMES; ADVERSE EVENTS; DRUG-TREATMENT; CHEMOTHERAPY; EPIDEMIOLOGY; METAANALYSIS; RIFAMPIN; LATVIA; PERU;
D O I
10.5588/ijtld.12.0481
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
SETTING: The Dominican Republic is a high-incidence area for multidrug-resistant tuberculosis (MDR-TB; 6.6% of initial cases). Standardised treatment regimens for MDR-TB may be a potential solution. OBJECTIVE: To present the effectiveness of standard regimens under routine national conditions. DESIGN: We reviewed all MDR-TB patients treated under routine conditions from 29 August 2006 to 30 June 2010, showing interim and final outcomes. Patients were treated with regimens that were standardised or individualised based on previously received second-line anti-tuberculosis drugs. RESULTS: Population description and culture conversion data are reported for the 289 MDR-TB patients. The median patient age was 31 years. Most had failed first-line treatment (72.6%). Culture negativity was obtained within 4 months (median 2 months) in 78.6%. Among the 150 patients treated between 2006 and 2008, 74% had favourable results on standardised and 66% on individualised regimens (P = 0.211). The efficacy of the standardised and individualised regimens was respectively 92.8% and 81% (P = 0.056). The relapse rate was approximately 1%. A median of five drug side effects occurred per patient. More than 2 months to culture conversion and bilateral cavitation on chest X-ray were found to be unfavourable outcome risk factors. CONCLUSIONS: Standardised MDR-TB regimens may be effective at the national level, even in resource-poor settings.
引用
收藏
页码:520 / 525
页数:6
相关论文
共 28 条
[1]  
Altman DG, 2000, Statistics with confidence, V2nd
[2]  
[Anonymous], 2010, WHO/HTM/TB/2010.3
[3]  
Bloss E, 2010, INT J TUBERC LUNG D, V14, P275
[4]  
Caminero JA, 2006, INT J TUBERC LUNG D, V10, P829
[5]  
Caminero JA, 2010, INT J TUBERC LUNG D, V14, P382
[6]   Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis [J].
Caminero, Jose A. ;
Sotgiu, Giovanni ;
Zumla, Alimuddin ;
Migliori, Giovanni Battista .
LANCET INFECTIOUS DISEASES, 2010, 10 (09) :621-629
[7]  
CANETTI G, 1963, Rev Tuberc Pneumol (Paris), V27, P217
[8]  
Coker R, 2002, INT J TUBERC LUNG D, V6, P649
[9]  
Espinal MA, 1998, INT J TUBERC LUNG D, V2, P490
[10]  
Geerligs WA, 2000, INT J TUBERC LUNG D, V4, P758